Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study-Reference-Cited by-同舟云学术

Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study

Published:2019-01-25 Issue:3 Volume:3 Page:333-342
ISSN:2509-4262
Container-title:PharmacoEconomics - Open
language:en
Short-container-title:PharmacoEconomics Open

Author:

Entrenas Costa Luis Manuel^ORCID,Casas-Maldonado Francisco,Soto Campos José Gregorio,Padilla-Galo Alicia,Levy Alberto,Álvarez Gutiérrez Francisco Javier,Gómez-Bastero Fernández Ana P.,Morales-García Concepción,Gallego Domínguez Rocío,Villegas Sánchez Gustavo,Mateos Caballero Luis,Pereira-Vega Antonio,García Polo Cayo,Pérez Chica Gerardo,Martín Villasclaras Juan José

Funder

Novartis Farmacéutica S.A.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Health Policy,Pharmacology

Link

http://link.springer.com/article/10.1007/s41669-019-0117-4/fulltext.html

Reference42 articles.

1. Lang DM. Severe asthma: epidemiology, burden of illness, and heterogeneity. Allergy Asthma Proc. 2015;36(6):418–24.

2. Sheehan WJ, Phipatanakul W. Difficult-to-control asthma: epidemiology and its link with environmental factors. Curr Opin Allergy Clin Immunol. 2015;15(5):397–401.

3. Alangari AA. Corticosteroids in the treatment of acute asthma. Ann Thorac Med. 2014;9(4):187–92.